A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE+)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04280718 |
Recruitment Status :
Active, not recruiting
First Posted : February 21, 2020
Last Update Posted : August 4, 2023
|
Sponsor:
argenx
Information provided by (Responsible Party):
argenx
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | March 1, 2027 |
Estimated Study Completion Date : | March 1, 2027 |